STERIS (STE)
(Delayed Data from NYSE)
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 10.26% and 0.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Don't Overlook Steris (STE) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Steris' (STE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Steris (STE) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Steris (STE) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
STERIS (STE) AST Business Expands, New Offerings Aid Growth
by Zacks Equity Research
STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
by Zacks Equity Research
STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Steris (STE) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unlocking Steris (STE) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore how Steris' (STE) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Steris (STE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Steris (STE) Matches Q4 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
The Zacks Analyst Blog Highlights Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS
by Zacks Equity Research
Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS are included in this Analyst Blog.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?